Zurich Cantonal Bank’s Harmony Biosciences HRMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$412K Sell
11,313
-2,056
-15% -$64.9K ﹤0.01% 2045
2026
Q1
$374K Buy
13,369
+5,192
+63% +$170K ﹤0.01% 1978
2025
Q4
$306K Hold
8,177
﹤0.01% 2053
2025
Q3
$225K Hold
8,177
﹤0.01% 2134
2025
Q2
$258K Hold
8,177
﹤0.01% 2016
2025
Q1
$271K Hold
8,177
﹤0.01% 1934
2024
Q4
$281K Buy
8,177
+3,028
+59% +$104K ﹤0.01% 1982
2024
Q3
$206K Hold
5,149
﹤0.01% 2092
2024
Q2
$155K Sell
5,149
-2,161
-30% -$65K ﹤0.01% 2162
2024
Q1
$245K Sell
7,310
-1,719
-19% -$55.2K ﹤0.01% 1939
2023
Q4
$292K Buy
9,029
+1,233
+16% +$34.4K ﹤0.01% 1855
2023
Q3
$255K Buy
7,796
+3,060
+65% +$106K ﹤0.01% 1816
2023
Q2
$167K Buy
4,736
+1,377
+41% +$47.5K ﹤0.01% 2042
2023
Q1
$110K Sell
3,359
-94
-3% -$4.28K ﹤0.01% 2239
2022
Q4
$190K Sell
3,453
-358
-9% -$19.7K ﹤0.01% 1845
2022
Q3
$169K Hold
3,811
﹤0.01% 1849
2022
Q2
$186K Sell
3,811
-1,246
-25% -$56.1K ﹤0.01% 1827
2022
Q1
$246K Buy
5,057
+727
+17% +$29.7K ﹤0.01% 1765
2021
Q4
$185K Buy
+4,330
New +$173K ﹤0.01% 2121

Other funds holding HRMY

Zurich Cantonal Bank's HRMY Position: Q2 2026 in Review

Zurich Cantonal Bank reduced its Harmony Biosciences (HRMY) stake by 15% in Q2 2026, selling an estimated $64.9K and leaving 11,313 shares worth $412K. The position accounts for ﹤0.01% of the portfolio, ranked #2045.

Zurich Cantonal Bank first reported a position in HRMY in Q4 2021 and has held it in 19 quarters since. 327 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

  • Zurich Cantonal Bank held 11,313 shares of Harmony Biosciences worth $412K as of Q2 2026.
  • Zurich Cantonal Bank sold 2,056 Harmony Biosciences shares in Q2 2026, an estimated $64.9K.
  • Harmony Biosciences made up ﹤0.01% of Zurich Cantonal Bank's portfolio in Q2 2026, its #2045 holding.
  • Zurich Cantonal Bank first reported a position in Harmony Biosciences in Q4 2021 and has held it in 19 quarters since.
  • 327 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on Zurich Cantonal Bank's 13F filing for Q2 2026, filed 12 Aug 2026.